Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the <scp>COVID</scp>‐19 Pandemic

Abstract

After 2 weeks, many participants with rheumatic diseases already had important changes to their health care, with many altering medications without professional consultation or because of hydroxychloroquine shortage. As evidence accumulates on the effectiveness of potential COVID-19 treatments, effort is needed to safeguard access to established treatments for rheumatic diseases.